![](\"https:\/\/mms.businesswire.com\/media\/20260622765504\/en\/2836639\/5\/MolMedBEmIF.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260622765504\/en\/766145\/5\/Feinstein_logo.jpg\"){kind=logo}
<\/a><\/a>\nMolecular Medicine<\/i>,<\/a> published in collaboration with Springer Nature\u2019s<\/i> BioMed Central, has achieved its highest impact factor (IF) since the journal\u2019s founding in 1994, raising its score to 8.3 from 6.4. Bioelectronic Medicine<\/i><\/a>, also published with BioMed Central, has received its first-ever impact factor of 6.8, marking a major milestone for the innovative journal.<\/p> \nAn impact factor is a key measurement of a journal\u2019s importance and influence within the scientific community. It is calculated by dividing the number of 2025\u2019s citations by the total number of articles published in the previous two years, according to analytics firm Clarivate. These scores help researchers determine where to publish their work and which journals to consult for foundational studies.<\/p> \n\u201cScience advances when researchers publish foundational work and build upon it with new experiments,\u201d said Kevin J. Tracey, MD<\/a>, president and CEO of the Feinstein Institutes, Karches Family Distinguished Chair in Medical Research and editor-in-chief of Bioelectronic Medicine.<\/i> \u201cThe high impact factors of both Molecular Medicine<\/i> and Bioelectronic Medicine<\/i> are evidence that leading researchers worldwide are turning to these journals as publication platforms for important new science.\u201d<\/p> \nMolecular Medicine<\/i> is now ranked among top journals; <\/b>38th out of 328 in the Biochemistry & Molecular Biology category and 40th out of 207 in the Cell Biology category. It receives thousands of research submissions each year. After a rigorous review process, the journal publishes approximately 10 percent of submitted manuscripts, and more than 460,000 papers have been downloaded to date.<\/p> \n\u201cThis is a significant achievement and a reflection of the dedication of our editorial team and the quality of research we publish,\u201d said Betty Diamond, MD<\/a>, director of the Institute of Molecular Medicine<\/a> at the Feinstein Institutes and editor-in-chief of Molecular Medicine.<\/i> \u201cImpact factors help inform fellow researchers about the reach and influence a medical journal has on the larger scientific community and why they should consider submitting their studies for publication. We are proud of this milestone and hope it encourages more scientists to share their important work with us.\u201d<\/p> \nBioelectronic Medicine<\/i> is now ranked 23rd out of 130 in the Engineering, Biomedical category and 42nd out of 330 in the Neurosciences category. The journal\u2019s inaugural IF is a testament to the growing interest in the field of bioelectronic medicine, a field significantly bolstered by the recent landmark approval of the first vagus nerve implant stimulator to treat Rheumatoid Arthritis by the Food and Drug Administration in 2025.<\/p> \nThe field of bioelectronic medicine \u2013 a convergence of molecular medicine, neuroscience and bioengineering \u2013 was pioneered at the Feinstein Institutes through the groundbreaking work of Dr. Tracey. The journal focuses on the use of implanted nerve-stimulating devices to measure, block, or regulate electrical signaling in the nervous system to treat diseases without pharmaceuticals. It bridges multiple disciplines \u2013 including material science, electrical engineering, artificial intelligence and immunology \u2013 and publishes research on precision neuromodulation, targeted pathways for managing conditions like arthritis and paralysis and closed-loop implantable systems.<\/p> \n\u201cReceiving our first impact factor of 6.8 is a major milestone for Bioelectronic Medicine<\/i> and reflects the groundbreaking work being done in this rapidly evolving field,\u201d said Valentin A. Pavlov, PhD<\/a>, professor in the Institute of Bioelectronic Medicine<\/a>, executive editor of Bioelectronic Medicine<\/i> and Molecular Medicine<\/i>. \u201cThis recognition validates the journal\u2019s mission to advance bioelectronic medicine and showcases the innovative research shaping the future of treating disease through neuromodulation.\u201d<\/p> \nResearchers interested in publishing in Molecular Medicine<\/i> can submit manuscripts online here<\/a>. Those interested in Bioelectronic Medicine can visit here<\/a>.<\/p> \nAbout the Feinstein Institutes\n